Forte Biosciences Inc (FBRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Forte Biosciences Inc (FBRX) has a cash flow conversion efficiency ratio of -0.166x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.00 Million) by net assets ($84.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See FBRX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Forte Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Forte Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Forte Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Forte Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kangstem Biotech Co. Ltd
KQ:217730
|
-0.056x |
|
Toro Ltd
NASDAQ:TORO
|
0.013x |
|
Group Eleven Resources Corp
V:ZNG
|
-0.080x |
|
Hyosung Chemical Corp
KO:298000
|
-0.068x |
|
Astral Resources NL
AU:AAR
|
-0.011x |
|
Iris Acquisition Corp II
NYSE:IRAB
|
0.000x |
|
Bluerock Acquisition Corp. Class A Ordinary Shares
NASDAQ:BLRK
|
10.328x |
|
ESAF Small Finance Bank
NSE:ESAFSFB
|
-0.810x |
Annual Cash Flow Conversion Efficiency for Forte Biosciences Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Forte Biosciences Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Forte Biosciences Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-30.75 Million | -0.586x | +27.93% |
| 2023-12-31 | $35.31 Million | $-28.71 Million | -0.813x | -285.51% |
| 2022-12-31 | $38.82 Million | $-8.19 Million | -0.211x | +47.47% |
| 2021-12-31 | $41.55 Million | $-16.68 Million | -0.401x | -28.50% |
| 2020-12-31 | $58.98 Million | $-18.42 Million | -0.312x | +35.23% |
| 2019-12-31 | $5.75 Million | $-2.77 Million | -0.482x | +18.65% |
| 2018-12-31 | $58.15 Million | $-34.47 Million | -0.593x | -35.35% |
| 2017-12-31 | $71.08 Million | $-31.13 Million | -0.438x | +89.63% |
| 2016-12-31 | $7.00 Million | $-29.54 Million | -4.222x | -684.24% |
| 2015-12-31 | $39.08 Million | $-21.04 Million | -0.538x | -- |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more